Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Examining Oncolytic Poliovirus Bioactivity in Tumor Tissue After Intratumoral Administration of PVSRIPO in Women With Triple Negative Breast Cancer

Trial Profile

Examining Oncolytic Poliovirus Bioactivity in Tumor Tissue After Intratumoral Administration of PVSRIPO in Women With Triple Negative Breast Cancer

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Recombinant polio virus vaccine Istari Oncology (Primary) ; Poliovirus vaccine live oral
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Pharmacodynamics
  • Sponsors Istari Oncology
  • Most Recent Events

    • 21 Sep 2018 Planned initiation date changed from 1 Sep 2018 to 24 Sep 2018.
    • 28 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 23 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top